PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

By Kanak Raina, Jing Lu, Y. Qian, M. Altieri, D. Gordon, AnnMarie K. Rossi, Jing Wang, Xin Chen, Hanqing Dong, Kam W. Siu and 4 more. Proceedings of the National Academy of Sciences of the United States of America, 2016

713 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/e217891a5797e4126c981fcc25473c6073f2f44f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. George M. Burslem
2. C. Crews

Citations in the corpus

• Proteolysis Targeting Chimeras as Therapeutics and Tools for Biological Discovery (2020, neutral): “, 2019) and castration-resistant prostate cancer (Raina et al., 2016) in preclinical models.”
• Lessons in PROTAC design from selective degradation with a promiscuous warhead (2017, background): “Proteins effectively degraded by PROTACs include RIPK2 and ERRa (Bondeson et al., 2015), BRD4 (Lu et al., 2015; Ohoka et al., 2017; Raina et al., 2016; Winter et al., 2015), BRD9 (Remillard et al., 2017), BCR/Abl and Abl (Lai et al., 2016; Ohoka et al., 2017), and ERa (Ohoka et al., 2017).”